Quantcast

Innovent can test its protein in patients with hemaological and advanced solid tumors

Innovent Biologics got approval from the National Medical Products Administration (NMPA) to start clinical trials for its IND application for IBI318, a recombinant fully human bispecific antibody targeting programmed cell death protein 1 (PD-1) and an undisclosed target for a tumor-associated antigen (TAA), in patients with hematological and advanced solid tumors.

Read more